NetScientific PLC - Ashford, Kent-based healthcare intellectual property commercialisation group - Portfolio company PDS Biotechnology Corp inks co-development agreement with Farmacore Biotechnology for Versamune-CoV-2FC, a Versamune-based vaccine aimed at preventing Covid-19 infection. Under the collaboration, PDS Biotech and Farmacore will accelerate development of Versamune-CoV-2FC into Phase 1 clinical testing in Brazil, with initial financial support provided by the Brazilian government. Versamune-CoV-2FC combines a Farmacore-developed recombinant SARS-CoV-2 protein with PDS Biotech's Versamune platform nanotechnology.
Current stock price: 6.10 pence
Year-to-date change: down 10%
By Tapan Panchal; tapanpanchal@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Netscientific (NSCI)